Sustainability Report 2013 Lek d.d.

Sustainability Report 2013 – Lek d.d. Environment 26 The indirect impact of transport is also taken into account in the process of selecting suppliers in categories such as placing orders for packaging materials (see Item 2.2.4). 34 EMAS Core Indicator, GRI Indicator G4-EN1 2.2.1 Recycling of hazardous and non-hazardous waste Waste reuse and recycling are integral parts of our API pro- duction processes. In 2013, we recycled and reused 91% of the total quantity of organic solvents, an increase of 2 per- centage points over the previous year. In Lendava, the lead- ing site in terms of waste reuse in recycling, the percentage of reused organic solvents amounted to as much as 97% (identical to the figure recorded in 2011 and 2012). Current- ly, a study of a project aiming to increase this proportion is being designed. The remaining solvents which, according to the pharmaceutical industry criteria, fail to achieve a level of purity sufficient for reuse are collected separately in ac- cordance with their composition and calorific value. Further treatment or disposal is the responsibility of authorized con- tract providers. At the Menge‰ site, non-halogenated solvent waste having a solvent content higher than 80% and being suitable for co- -incineration in a natural gas burning device is used as a secondary fuel for the operation of a device generating heat and vapour for manufacturing purposes. Since adequate combustion conditions are provided, emissions generated, in the process are comparable to those resulting from the combustion of environment-friendly energy resources such as natural gas and possibly industrial fuel. In the field of non-hazardous waste, systemic upgrades of segregation, collection and preparation of waste for recycling are continuously performed. All biodegradable waste (waste mycelium, waste purple coneflower (Echinacea) and fennel plants, was redirected to a bio-gas works for reprocessing. 2.2.2 Mass flow of materials Changes in the structure and volume of pharmaceutical production cause the annual fluctuation of mass flow of ma- terials at the corporate level. The increase of mass flow of materials in 2011 and 2012 was followed by a decrease in 2013 at both the Menge‰ as well as Ljubljana site. There is no such fluctuation at the Lendava production and Preva- lje sites, where one to two products are manufactured and as there, the change in the volume of API production also means an increase in the use of raw materials. 2.2 Raw materials and natural resources * Total quantity of materials purchased within the reporting period to ensure smooth progress of the manufacturing process to the finished product phase (including packaging but exclusive of fuels, water and manufacturing equipment). 2009 t 6,080 7,232 11,467 3,473 28,252 2010 t 6,456 9,015 14,404 3,513 33,388 2011 t 6,811 8,804 16,898 3,858 36,371 2012 t 7,548 9,861 15,707 3,979 37,095 2013 t 8,594 8,177 14,497 4,285 35,552 Year Unit Lendava Ljubljana Prevalje Menge‰ Lek (Total) Table 3: Annual mass flow of various materials used* (in t) 34 2.2.3 Efficiency of materials The graphic display of the efficiency of the use of all the raw materials at Lek d.d. reflects the intensive efforts to reduce the consumption of raw materials per unit of product. The quantity of raw materials used per tonne of API / product started to fall after 2010. In 2013, the reduction was more than 5%, compared to the previous year and in the 2010- 2013 period an almost 13% reduction. The increasing efficiency of the use of materials is demon- strated in Graph 2. Due to the extensive range of active ingredients and pro- ducts, and as a result of changes to the product portfolio, the efficiency of the use of raw materials at the Ljubljana and Menge‰ site cannot be seen from the graph. For this purpose, an overview by product would be required since their production output varied significantly. Efficiency of the use of raw materials strongly depends on the range of pro- ducts manufactured at the Menge‰ site. These are integrat- ed into the product only to a minor extent, and are mostly used in the process of finished product manufacture. By reviewing the method for acquiring data on the realiza- tion of finished pharmaceutical products at the Ljubljana site, the accuracy of the data on the efficiency of the use of raw materials improved in 2013.